1. Home
  2. BCDA vs DUO Comparison

BCDA vs DUO Comparison

Compare BCDA & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • DUO
  • Stock Information
  • Founded
  • BCDA N/A
  • DUO 2011
  • Country
  • BCDA United States
  • DUO China
  • Employees
  • BCDA N/A
  • DUO N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • DUO Real Estate
  • Sector
  • BCDA Health Care
  • DUO Finance
  • Exchange
  • BCDA Nasdaq
  • DUO Nasdaq
  • Market Cap
  • BCDA 11.0M
  • DUO 11.4M
  • IPO Year
  • BCDA N/A
  • DUO 2019
  • Fundamental
  • Price
  • BCDA $2.12
  • DUO $2.32
  • Analyst Decision
  • BCDA Strong Buy
  • DUO
  • Analyst Count
  • BCDA 1
  • DUO 0
  • Target Price
  • BCDA $25.00
  • DUO N/A
  • AVG Volume (30 Days)
  • BCDA 204.0K
  • DUO 177.1K
  • Earning Date
  • BCDA 08-12-2025
  • DUO 08-29-2025
  • Dividend Yield
  • BCDA N/A
  • DUO N/A
  • EPS Growth
  • BCDA N/A
  • DUO N/A
  • EPS
  • BCDA N/A
  • DUO 7.57
  • Revenue
  • BCDA $3,000.00
  • DUO $46,458,330.00
  • Revenue This Year
  • BCDA N/A
  • DUO N/A
  • Revenue Next Year
  • BCDA N/A
  • DUO N/A
  • P/E Ratio
  • BCDA N/A
  • DUO $0.31
  • Revenue Growth
  • BCDA N/A
  • DUO 19.00
  • 52 Week Low
  • BCDA $1.63
  • DUO $1.97
  • 52 Week High
  • BCDA $4.66
  • DUO $74.72
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 44.60
  • DUO 37.94
  • Support Level
  • BCDA $1.98
  • DUO $1.97
  • Resistance Level
  • BCDA $2.45
  • DUO $2.49
  • Average True Range (ATR)
  • BCDA 0.16
  • DUO 0.17
  • MACD
  • BCDA -0.01
  • DUO 0.02
  • Stochastic Oscillator
  • BCDA 18.00
  • DUO 45.86

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About DUO Fangdd Network Group Ltd.

Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.

Share on Social Networks: